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Efficacy of aldose reductase 
inhibitors is affected by oxidative 
stress induced under X-ray 
irradiation
Albert Castellví1,6, Isidro Crespo1, Eva Crosas1,5, Ana Cámara-Artigas2, José A. Gavira3, 
Miguel A. G. Aranda1, Xavier parés4, Jaume Farrés4 & Judith Juanhuix  1
Human aldose reductase (hAR, AKR1B1) has been explored as drug target since the 1980s for its 
implication in diabetic complications. An activated form of hAR was found in cells from diabetic 
patients, showing a reduced sensitivity to inhibitors in clinical trials, which may prevent its 
pharmacological use. Here we report the conversion of native hAR to its activated form by X-ray 
irradiation simulating oxidative stress conditions. Upon irradiation, the enzyme activity increases 
moderately and the potency of several hAR inhibitors decay before global protein radiation damage 
appears. The catalytic behavior of activated hAR is also reproduced as the KM increases dramatically 
while the kcat is not much affected. Consistently, the catalytic tetrad is not showing any modification. 
The only catalytically-relevant structural difference observed is the conversion of residue Cys298 to 
serine and alanine. A mechanism involving electron capture is suggested for the hAR activation. We 
propose that hAR inhibitors should not be designed against the native protein but against the activated 
form as obtained from X-ray irradiation. Furthermore, since the reactive species produced under 
irradiation conditions are the same as those produced under oxidative stress, the described irradiation 
method can be applied to other relevant proteins under oxidative stress environments.
The increase in the flux of the polyol pathway is the main mechanism by which hyperglycemia leads to diabetic 
complications, such as microvascular and macrovascular damage. This pathway is followed by only 3% of the 
cytosolic glucose in physiological conditions but increases to more than 30% under hyperglycemic conditions1,2. 
The key step in this pathway is the reduction of glucose to sorbitol catalyzed by aldose reductase (hAR, AKR1B1), 
a member of the NAD(P)H-dependent aldo-keto reductase superfamily1–6. One of the first cellular deleterious 
effects is NADPH depletion, reducing its availability for the regeneration of the powerful antioxidant glutathione 
(GSH) and weakening intracellular antioxidant defenses2,5,7,8. Moreover, in the second step of the polyol pathway, 
sorbitol is metabolized by sorbitol dehydrogenase to fructose at the expense of producing additional NADH, 
which potentially increases the reactive oxygen species (ROS) via NADH oxidase and electron leakage in the 
electron transport chain8,9. The inhibition of hAR would therefore block the polyol pathway, counteracting signif-
icantly the unbalanced conditions caused by intracellular oxidative stress typical of diabetes.
Aldose reductase inhibitors (ARIs) have been indeed the focus of research for over 40 years since the discovery 
of the involvement of hAR in diabetic processes2. Unfortunately, the attempts to find an effective drug targeting 
hAR under diabetic conditions have been unsuccessful so far. Although several inhibitors have been reported to 
effectively block the hAR activity in vitro using purified protein7, their potency is severely reduced when tested 
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in clinical trials. Early on, this effect was hypothesized to be related to the generation, in significant amounts, of 
an activated form of hAR under oxidative stress conditions, which differs from the native form in its kinetic con-
stants and a marked reduction to ARIs sensitivity10–12. Remarkably, it has been shown that hAR can be activated 
also in vitro by mutagenesis of Cys298 residue (C298S13,14, C298A14,15), which has been identified as the main 
target for various oxidative modifications16–19, or by the incubation of the enzyme with chemical compounds20. 
The study of ARIs therefore requires the use of this hAR form present under intracellular oxidative stress condi-
tions found in diabetes, which differs from the native form expressed in physiological conditions or prepared by 
recombinant techniques.
The oxidative stress causing metabolic abnormalities in cells exposed to hyperglycemia is mainly produced 
by the accumulation of intracellular free electrons and reactive oxygen species (ROS), notably O2●−, H2O2 and 
OH●, among others21. Cellular oxidative stress can not be reproduced in vitro due to the complexity and diversity 
of factors influencing this condition. In consequence, in vitro studies under oxidative stress conditions utilize 
indirect methods to produce the same reactive species as those produced in vivo, such as the addition of chemical 
compounds. Another common method, which bypasses the potential bias in the result interpretation that the use 
of a particular chemical compound might introduce, is to employ electrons or ionizing radiation to create radical 
species in protein solutions22–28. As documented extensively in the literature, the radical species induced by irra-
diation are the same than those present under oxidative stress conditions21,29. The use of X-rays of a wavelength 
of ~1 Å (12.4 keV) is particularly convenient as the energy is deposited evenly over a thickness in the millimiter 
range or less in protein solutions or crystals. Here we employ synchrotron X-ray irradiation at that wavelength 
to report a modification of hAR which reproduces the behavior of the activated form generated under diabetic 
oxidative stress conditions. This modification has been characterized by enzymatic assays after exposition of hAR 
in solution under different irradiation doses, by monitoring the progressive structural changes of hAR crystals as 
irradiation dose increases and by characterizing the structural changes in solution using mass spectrometry. The 
activity of the in-vitro potent ARIs Zenarestat30, JF004831, Epalrestat32 and Tolrestat33 was also checked at different 
irradiation doses. A mechanism for the activation of hAR under oxidative stress conditions is proposed and some 
suggestions for the structure-based drug design targeting hAR are provided.
Results
X-ray irradiated hAR behaves as the activated form in enzymatic assays. Enzymatic assays reveal 
that the activity of hAR at a concentration of 2.3 mg/mL increases moderately by ~50% when it receives a dose 
between 1 and 2 kGy, as compared to the non-irradiated protein, without significant general structural changes 
as shown by Small Angle X-ray Scattering (SAXS) measurements (Fig. 1a). The radius of gyration (Rg) of hAR 
in solution remains constant within 0.1 nm variation, which is a well-stablished criterion to assess the preser-
vation of the global protein structure under irradiation34,35, until the protein receives a dose of ~1 kGy. Above 2 
kGy, the relative activity of hAR decays concomitantly with the dramatic increase of the radius of gyration as a 
consequence of radiation damage36. The inhibitory effect of in-vitro potent ARIs Zenarestat, JF0048, Epalrestat 
and Tolrestat was checked for non-irradiated hAR, for hAR irradiated to the point where the highest activity is 
reached without significant protein unfolding or aggregation (1 kGy) and for over-irradiated, damaged hAR (8 
kGy) (Fig. 1b). While inhibiting native non-irradiated hAR, the studied compounds were significantly less effec-
tive in irradiated hAR. The kinetic analysis of non-irradiated and irradiated hAR at 1 kGy (Fig. 1c) shows that 
the catalytic constant kcat value remains unaltered (kcat0kGy = 45.0 ± 3.0 min−1 vs kcat1kGy = 46.4 ± 3.5 min−1) while 
the Michaelis constant KM value exhibits a 7-fold increase under irradiated conditions (KM0kGy = 55.3 ± 13.1 µM 
vs KM1kGy = 382.8 ± 141.6 µM). In agreement with previous reports10,11,20,37, non-irradiated hAR is inhibited by 
over-saturating concentrations of the substrate d,l-glyceraldehyde. Conversely, irradiated hAR is not inhibited by 
Figure 1. Activation of hAR with irradiation. (a) Evolution of hAR normalized mean activity (red circles) 
and radius of gyration, Rg (gray triangles), as a function of dose. At 6 mM D,L-glyceraldehyde substrate 
concentration, enzymatic activity increases with irradiation dose until hAR undergoes major structural changes 
due to radiation damage. (b) Inhibitory potency of Zenarestat (black bars), JF0048 (gray bars), Epalrestat (light 
gray bars) and Tolrestat (white bars) at 0 kGy, 1 kGy and 8 kGy doses. Tested concentrations close to the IC50 
value were used for each compound. The non-normalized specific activities of the inhibitors are found in Supp. 
(c) Effect of irradiation on hAR kinetics. Native enzyme without irradiation loses 50% of its activity due to 
excess-substrate inhibition at 6 mM d, l-glyceraldehyde (red circles). Irradiation with a dose of 2 kGy increases 
the value of the Michaelis constant KM towards substrate by near one order of magnitude (7 times) while the 
inhibition disappears (blue circles).
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its substrate at any of the working substrate concentrations, as previously reported for the activated hAR10,11,20,37. 
This behavior is consistent with the higher activity of the irradiated protein with respect to native non-irradiated 
protein at 6 mM d,l-glyceraldehyde, while maintaining a similar kcat value. In conclusion, the 1-kGy irradiated 
form of hAR solution at 2.3 mg/mL and the activated form of hAR found under hyperglycemic and activation 
conditions12,38 show the same behavior in the enzymatic analyses of the control hAR and the hAR in the presence 
of the ARIs. X-ray irradiation is thus able to reproduce the functionality of hAR under oxidative stress conditions.
The only change in the crystallographic structure with accumulated dose is the modification of 
Cys298. The effects of the X-ray irradiation on the hAR structure were monitored by macromolecular crystal-
lography (MX). Twenty datasets (D1-D20) were collected at 100 K from one single crystal of hAR co-crystallized 
with NADPH by a large homogeneous X-ray beam profile at the XALOC synchrotron beamline39. The absorbed 
dose per each data set in the exposed region was 0.03 MGy. The crystal was irradiated with an absorbed dose 
of 0.15 MGy between consecutive datasets, so that the total dose received by the crystal was 3.45 MGy. Data 
collection statistics for all datasets and refinement statistics for D1 and D20 datasets are shown in Sup. Table 1. 
Remarkably, the resolution of the datasets experiences a constant, modest degradation from 0.92 Å in dataset D1 
to 1.17 Å in dataset D20. We incidentally note that the doses absorbed by the cryocooled crystals are not to be 
compared with the absorbed doses by the protein solution at room temperature, as the effects of the radiation 
damage strongly depend upon the protein concentration40 and the temperature36,41. Rather than comparing the 
actual dose, a coarse correspondence on the radiation damage effects can be established between experiments 
employing cryocooled protein crystals and those using protein solution at room temperature cas the global struc-
ture of the protein is preserved in MX and SAXS experiments, respectively.
While the backbone structure remains unchanged, the difference Fourier maps, Fobs,n − Fobs,1, reveal side-chain 
movements and specific radiation damage throughout the entire structure as accumulated absorbed dose 
increases. Signs of specific damage were not observed in the catalytic tetrad Tyr48, Lys77, His110 and Asp4342 
(Fig. 2), which consistently agrees with the similar experimental kcat values measured with the non-irradiated 
and irradiated enzyme. No conformational changes were observed at any irradiation dose in the other residues 
forming the active site of the protein except for the remarkable alteration on Cys298, which was developing upon 
irradiation (Fig. 3). This residue has been reported to regulate the kinetic and inhibition properties of the enzyme 
although it does not participate in the catalysis13,14,16.
Three different structural changes, seen as differential electron densities (blobs) in the difference Fourier maps 
at a resolution of 1.17 Å (Fig. 3a), can be observed in Cys298 as absorbed dose increases: a loss of electron density 
(red blob) accounting for the disorder and desulfuration induced by the irradiation, a small increase of the elec-
tron density (green blob pointed by blue arrows) compatible with an induced movement of the residue towards 
this region (Supp. Fig. 2), and the emergence of a positive electron density (green blob pointed by green arrows) 
at a distance of 1.47 Å from the Cβ-Cys298 atom for map D20-D1. This latter positive electron density is also 
observed in Fo-Fc electron density maps with progressively increasing absorbed dose (Fig. 3b). The maximum 
value of this positive electron density in the Fo-Fc map at the highest-dose dataset D20 is placed at a distance of 
1.46 Å from the Cβ-Cys298. This distance falls well within the typical covalent C−O distances in both difference 
Fourier and Fo-Fc maps, suggesting that the new electron density can be explained by the capture of an oxygen 
atom from the solvent (probably from OH·) by a radicalized intermediate species. This process would effectively 
change the Cys298 residue present in the native form to a serine residue. The refinement of a serine and cysteine 
sharing the same Cβ at the 298 position, which is the model with the minimum number of refined variables to 
avoid over-refinement, leads to unrestrained distances between Cβ atom and Oγ and Sγ atoms of 1.41 ± 0.08 Å 
and 1.80 ± 0.03 Å, respectively (Fig. 3c). These distances are in excellent agreement with the tabulated values of 
1.417 Å and 1.801 Å, respectively43. Moreover, the unrestrained distance between Cβ and Oγ atoms is constant for 
all datasets taken at different doses (Fig. 3e), suggesting that the bond is stable and thus the residue in this state 
can properly be identified as serine. Sγ-Cys298 and Oγ-Ser298 are well-defined atoms, as hinted by their atomic 
displacement parameter (ADP) values (12.24 Å2 and 15.64 Å2, respectively), which are similar to that of the Cβ 
atom (14.67 Å2).
The refined free occupancies for Sγ-Cys298 and Oγ-Ser298 at the maximum absorbed dose (dataset D20) are 
0.68 and 0.25, respectively. As the overall occupancy for both species is lower than one, further minor concurrent 
species can be hypothesized to be coexisting with either a cysteine or a serine in the 298 position. Same hypothesis 
can be proposed from the evolution with absorbed dose of the electron density peaks in the difference Fourier 
maps (Fig. 3d). The sum of the maximum intensity of the blobs attributed to the cysteine desulfuration (Fig. 3d, 
pink circles) and the blob assigned to the Oγ capture (Fig. 3d, green squares) is consistently less than one for all 
datasets (Fig. 3d, gray triangles) and increasing with dose, suggesting that these putative extra species in residue 
298 would be present in all the doses and that these are created by the X-ray irradiation (Fig. 3d, gray triangles).
Liquid chromatography tandem mass spectrometry reveals C298S and C298A modifications. 
Specific changes in Cys298 were also checked by liquid chromatography tandem mass spectrometry (LC-MS/MS) 
for the non-irradiated (0 kGy) and for the 1-kGy and 17-kGy irradiated proteins (Fig. 4 and Supp. Fig. 3). The 
Cys298-containing peptides were selected after trypsin digestion and fragmented into smaller ionized peptides. 
As expected, non-irradiated samples showed no modifications at any residue position (Fig. 4a). At an irradiation 
level matching the maximum activity peak of hAR (1 kGy), only two different modifications were detected along 
the peptide sequence: C298S and C298A (Fig. 4b). Over-irradiated samples at 17 kGy showed a C303A modifica-
tion in addition to the C298S and C298A modifications (Supp. Fig. 3), which points to desulfuration of Cys303 by 
radiation damage. LC-MS/MS measurements thus are consistent with the C298S modification seen in MX exper-
iments in irradiated samples, and suggest that the C298A modification is one of the extra species hypothesized at 
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the 298 position in MX experiments. We do not discard that other species already reported in literature, such as 
sulfenic acid, could also be present44,45.
Modeling of the active site with and without inhibitor shows why inhibitors are not effective 
in the activated form. Although Cys298 is not a catalytic residue in hAR, the conversion of this residue 
into a Ser or Ala is key in the functional properties of hAR and in the sensitivity to ARIs. This is explained by 
the localization of Cys298 between the substrate-binding pocket and the active site, where NADP+ and the 
catalytic tetrad are found. Cys298 is therefore controlling the substrate accessibility to the active site. The crys-
tallographic structure reveals that the conversion of the Cys298 residue (Fig. 5a) into a serine (Fig. 5b) changes 
the position of the atom in the γ position of the residue and the type of element, thus modifying the entrance to 
the substrate-binding pocket. The protein-ligand interaction may be consequently affected. This view is consist-
ent with the enzymatic results described above, which show an increase in the KM value and a reduction in the 
potency of the tested inhibitors.
The steric changes in the entrance of the binding pocket severely hinder the interactions between hAR and 
the inhibitors originally designed against the native form, including a cysteine in the 298 position (Fig. 5). The 
alignment between the D20 dataset crystallographic structure and that with the various inhibitors shows that the 
Sγ-Cys298 atom has a very low displacement (Supp. Table 3). The distances of the Sγ-Cys298 atom to the closest 
Figure 2. Absence of specific radiation damage in the binding pocket and in the catalytic tetrad. (a) Difference 
Fourier map (Fobs,20 − Fobs,1, αcalc,1) of the most irradiated dataset, D20. The NADPH (pink) and a citrate 
molecule (yellow) are bound to the binding pocket. The residues of the catalytic tetrad are shown in cyan and 
Cys298 in navy blue. No signs of specific radiation damage are observed in the vicinity of the binding-pocket 
surface, except for the Cys298 residue. The map was contoured at 0.56 e/Å3 (σ = ±5). (b) Detail of the difference 
Fourier maps (Fobs,10 − Fobs,1, αcalc,1) (top row) and (Fobs,20 − Fobs,1, αcalc,1) (bottom row) on the catalytic tetrad 
(Asp43, Lys77, His110 and Tyr48) at 1.2 Å resolution, calculated using the amplitudes of datasets D10 or D20 
and the initial data set D1 and the phases αcalc,1 of D1. The maps do not reveal signs of specific radiation damage 
in the residues of the catalytic tetrad. The D10-D1 and D20-D1 difference Fourier maps of the catalytic tetrad 
were contoured at 0.33 e/Å3 (σ = ±4.97 and σ = ±2.97, respectively).
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atom of the studied inhibitors can thus be compared, and are shown to be always above 3 Å. The native form is 
therefore sterically compatible with the inhibitors, as expected since they were designed against it as a target. On 
the other hand, in the irradiated protein where cysteine has been replaced with serine, the distance between the 
Oγ-Ser298 atom and the closest atom of the aligned inhibitors is much shorter and could lead to steric collisions 
that may affect their binding to the active site. Remarkably, Tolrestat, which had the highest inhibitory potency 
among the tested compounds on the irradiated enzyme (Fig. 1), also shows the longest distance between its clos-
est atom and the Oγ-Ser298 atom, 2.6 Å. This fact reinforces the view that the activated form of hAR interacts less 
efficiently with inhibitors due to the conversion of Cys298 into Ser298 under oxidative stress conditions.
The activation of hAR is mediated by the free electrons present under oxidative stress condi-
tions. Specific radiation damage in MX experiments at cryogenic temperatures results essentially from the 
action of secondary electrons that are generated by the photoelectrons ejected from water and organic molecules. 
The secondary electrons are highly mobile and can either be spread through the solvent or be tunneled into 
the protein structure through the main chain until they find electrophilic sites such as metal centers and acidic 
or sulfur-containing residues, especially cysteine46. The other reactive species generated from water radiolysis 
show low mobility at cryogenic temperatures and their effect on the structural damage can be neglected. To test 
whether the loss of the thiol group in Cys298 of hAR, observed by MX experiments at cryogenic temperature. 
can be attributed to electron capture as well in protein solution at room temperature, the relative activity of hAR 
was measured as a function of dose in the presence of different compounds with variable scavenging properties 
depending on the reactive species (Fig. 6).
Uridine has recently been reported effective only against radiation damage at room temperature and inef-
fective at cryogenic temperatures36. As the electrons are the main mobile reactive species at cryogenic tempera-
tures47, this suggests that uridine is only effective against ROS and not against free electrons and therefore it may 
Figure 3. Specific changes in Cys298 as a function of dose. (a) Difference Fourier maps (Fobs,n − Fobs,1, αcalc,1) 
on Cys298 residue at 1.2 Å resolution, calculated between each dataset n and the initial dataset using the phases 
of the fresh, not previously irradiated dataset, αcalc,1. The difference Fourier maps are contoured at two different 
electron density sigma levels (0.145 e/Å3 for the first row, 0.267 e/Å3 for the second row) for clarity. The maps 
have sigma levels ranging from σ = ±9.00 (D2-D1 map) to σ = ±2.53 (D8-D1 map) for the first row, and from 
σ = ±3.99 (D10-D1 map) to σ = ±2.41 (D20-D1 map) for the second row. Electron densities colored in green 
and red represent positive and negative sigma levels, respectively. Red blobs are indicative of the loss of electron 
density due to movements and desulfuration of Cys298; green blobs pointed by blue arrows show the increase of 
electron density due to displacements of Cys298 and green blobs pointed by green arrows reveal the appearance 
of a new atom in the vicinity of Cys298. (b) Electron density maps at 0.92–1.17 Å resolution on the Cys298 
residue as a function of dose. In blue, 3Fo-2Fc electron density maps at σ = 1.00; in green, Fo-Fc electron density 
maps at σ = 2.50. (c) The Cys298/Ser298 amino acid is well fit in the 2Fo-Fc electron density map at σ = 1  
for the D20 dataset. The Fo-Fc map at σ = ±2.50 does not show any electronic density. (d) Occupancy-related 
electron density maxima versus dataset. Red circles: occupancy-related electron density of Sγ atom decreases 
as Cys298 is desulfurated and the Sγ atom moves; green squares: occupancy-related electron density of Oγ 
atom increases as the Ser298 is formed; pink circles: loss of the electron density of the Sγ atom due to the 
desulfuration, calculated as the difference between the two previous electron densities; gray triangles: difference 
between the electron densities related to the desulfuration of Cys298 (pink circles) and the formation of the 
Ser298 (green squares). (e) Distances measured in the difference Fourier maps from the Cys298-Cβ atom to 
the center of the green blobs indicated by green arrows in (a) versus dataset. The top and bottom dashed lines 
represent the tabulated distances Cβ-Sγ and Cβ-Oγ in cysteine and serine residues, respectively.
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be a probe to test the action of free electrons in the activation process. The relative activity of hAR in the presence 
of 10 mM uridine (Fig. 6a, red dots) is similar to that of hAR without a scavenger (Fig. 1a). In both cases the 
relative activity increases by ~50% at 1 kGy and follows a sigmoidal decay at higher doses. Uridine is thus not pre-
venting the production of the activated form of hAR under X-ray irradiation by the action of its ROS scavenging 
properties. Nevertheless, uridine still prevents global radiation damage to hAR since the dose at which the enzy-
matic activity is reduced to the half with respect to the maximum relative activity is increased from 10.9 ± 0.8 kGy 
without uridine (Fig. 1a) to 26 ± 2 kGy with 10 mM uridine (Fig. 6a). The uridine protective effect is also observed 
in the conservation of the relative radius of gyration of hAR in solution as measured by SAXS (Supp. Fig. 4). To 
further assess the action of electrons in the activation of hAR, sodium nitrate, a well-known electron scavenger48, 
was added to the solution of hAR with 10 mM uridine. By adding 40 mM sodium nitrate, the relative activity 
of hAR increased only by 25% at 1 kGy with respect to non-irradiated sample, and decreased at higher doses 
with a sigmoidal behavior (Fig. 6a). Remarkably, this activity increase in the presence of sodium nitrate (~25%) 
was significantly lower than that obtained with uridine only, which is fully compatible with the electron capture 
as the main source of activation of hAR. Electron capture is also consistent with the quantity of non-thiolated 
cysteines per hAR molecule as a function of dose measured by the Ellman’s assay (Fig. 6b). The number of buried 
non-thiolated cysteines per molecule decays as a function of dose, whereas the number of cysteines accessible to 
the Ellman’s reagent per molecule remains approximately constant.
The activities at different doses and scavengers allow drawing an hypothesis of the mechanism for the con-
version of residue Cys298 into Ser298 and to Ala298 based on the cysteine desulfuration involving highly mobile 
electrons either from the solvent or tunneled through the backbone and absorbed by hAR electrophilic centers 
such as sulfur atoms46,49,50. This hypothesis is reinforced by the desulfuration of non-exposed cysteines observed 
in our MX experiments under cryogenic conditions, in which electrons are essentially the only mobile reactive 
species51. Whichever the origin of the free electrons is, after the absorption by the cysteine and the loss of the 
thiol group, residue 298 enters in an excited, metaestable state49,50 which can bond either to a hydroxyl group to 
form a serine or to a hydrogen radical to form an alanine (Fig. 6c). At this stage we cannot exclude other products 
generated by alternative or complementary mechanisms.
Discussion
The activated form of hAR, as found under oxidative stress conditions in cellulo, has been reported to have different 
kinetic constants than the native form, in particular a much larger KM value and a more stable kcat value13,14,52, and 
to reduce the efficacy in clinical trials of ARIs developed and tested in vitro13,15,52. Here we have reproduced this 
characteristic behavior of the activated hAR in irradiated native protein solution. X rays are massively absorbed 
by the ~1000 mg/mL water content of the solution, rather than the protein at a concentration of 2.3 mg/mL, 
and they induce the same reactive species as those present under oxidative stress conditions21,29, where the acti-
vated form has been found10,12.
A generic unwanted side effect of using X-ray radiation to induce reactive species is to produce global struc-
tural changes in the protein as a consequence of the primary interaction of X rays with the protein atoms. These 
structural changes, which would not be produced in cells under oxidative stress conditions, could in principle 
limit the capacity of irradiation methods to mimic the catalytic behavior under stress conditions. In this respect, 
Figure 4. LC-MS/MS analysis. LC-MS/MS spectra for non-irradiated protein (b) and for the irradiated 
protein at 1 kGy subjected to modifications at position 298 from cysteine to serine (b) and alanine (c). 
Characteristic peaks from the peptide fragmentation are colored in red (bn), blue (yn) and green (precursor). 
Non-characteristic peaks from the sequence are marked in gray. For clarity, only peaks that contain information 
about modifications are labeled. Only peaks above 1% of the base peak and with match tolerance of 0.6 Da are 
represented.
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our data do not discard conclusively that there are no such global structural changes at doses up to 1 kGy, when 
the values of the kinetic constants and the reduced potency of ARIs suggest a significant activation of hAR. 
However, our data support that, in case there was such global radiation damage on the protein, it is not affecting 
the catalytic reaction, as the kcat value does not change at this dose level. Contrarily, the existence of relevant spe-
cific changes is supported by the dramatic increase in the KM value, indicating that the interaction with the sub-
strate is severely affected. The hypothesis that better matches this behavior of the kinetic parameters is a change 
in the d,l-glyceraldehyde substrate binding pocket. The Cys298 residue, which lies at the entrance of the binding 
pocket, is an excellent candidate for this change. This hypothesis is consistent with previous literature, which 
Figure 5. Changes on the topology of the hAR pocket entry channel and steric collisions of activated hAR 
with inhibitors. The conversion of Cys298 into Ser298 modifies the entrance of the substrate-binding pocket. 
(a) Entrance of the binding pocket of the native form of hAR. The sulfur atom of the Cys298 residue is marked 
in yellow. (b) Entrance of the binding pocket of the irradiated structure, which shows the Oγ-Ser298 atom, 
marked in red. In both cases, the nicotinamide ring of the cofactor is shown in pink color. (c–f) Interaction 
of the studied inhibitors with Cys298 and Ser298. The structure of the D20 dataset (in cyan) is superimposed 
with the crystallographic structures of hAR including the inhibitors Zenarestat (c, purple, PDB 1IEI), JF0048 
(d, magenta, PDB 4XZH), Epalrestat (e, orange, PDB 4JIR) and Tolrestat (f, gray, PDB 1AH3). In all cases the 
inhibitors, designed against the native form, show severe steric collisions with Oγ-Ser298 but not with Sγ-
Cys298. Sulfur atoms are displayed in yellow whereas oxygen atoms are displayed in red.
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shows that the mutation of Cys298 increases the KM value by one order of magnitude without severely affecting 
the kcat value13,14,52.
As radiation damage is expected to induce a loss of the catalytic activity, it is noticeable that the activity of hAR 
in solution increases by 50% when irradiated up to 1 kGy (Fig. 1a). This moderate increase in the activity can be 
explained by the saturation at higher concentrations of the d,l-glyceraldehyde substrate which in turn leads to 
the loss of substrate inhibition, as indicated by the dramatic increase of the KM value (Fig. 1c). Consistently, the 
activity blockade by the ARIs, which also bind to the d,l-glyceraldehyde pocket, is also reduced (Fig. 1b).
The structural studies at atomic resolution are in line with our proposed hypothesis that the presence of a 
serine or alanine in residue 298 instead of cysteine in an oxidative stress environment is causing the activation of 
the hAR. Other species reported to oxidize Cys298 such as sulfenic acid can not be excluded45 to intervene in the 
activation. Irradiation of the native form induces the same structural changes at atomic level as those suggested 
for the activated form12,14,37,53, that is, the modification of the residue 298 while the catalytic tetrad, as well as all 
the other residues around the binding pocket, remain unaltered (Fig. 2). According to the results presented here, 
the activated form differs structurally from the native form by the replacement of the Cys298 residue by Ser298 
and, to a lesser extent, by Ala298. We can not exclude further changes at this position which might as well mod-
ify the interaction with ARIs. The modification of this key residue affects the entrance to the substrate-binding 
pocket, resulting in a altered binding of the substrate and of the inhibitors, which finally leads to a reduction in 
the inhibitory potency of the drugs initially designed to bind to the native form of hAR.
Incidentally, we note that more substrates other than d,l-glyceraldehyde might be tested. However, given that 
glyceraldehyde is one of the smallest substrates for hAR, the accessibility of this substrate to the binding pocket 
is high, as it can be accommodated into the altered binding pocket more easily than other common, larger sub-
strates such as glucose, xylose or 4-hydroxynonenal, among others. Therefore, it can be expected that the potency 
loss of the inhibitor compounds observed using glyceraldehyde as a substrate will also appear at least in a similar 
extent using other common substrates under the same oxidative stress conditions.
The conversion of the residue Cys298 into Ser298 and Ala298, and possibly other species, is hypothesized to 
be triggered by the presence of free electrons available under X-ray irradiation, as indicated by the lesser increase 
of activity upon irradiation in the presence of sodium nitrate (a known free electron scavenger) compared to 
the higher increase when adding uridine (a ROS scavenger) in the solution. The free electrons might be either 
induced in the solvent or tunneled into the protein structure through the protein main chain.
In spite of the degradation of the modified proteins and the continuous expression of the native form in living 
cells, the described activated forms prevail in cells from diabetic patients as the proteins newly expressed are 
modified recurrently under permanent oxidative stress conditions. Therefore, we propose that ARIs should be 
designed against the activated forms of hAR, here generated by X-ray irradiation, which show a similar behavior 
against ARIs to the activated forms of hAR found under hyperglycemic conditions10,11,20. The attempts to develop 
ARIs employing the native, genome coded form of hAR risk to fail when tested in real diabetic tissues or patients, 
as it happened in many previous cases10,11. In particular, ARIs should be designed excluding the interaction of the 
inhibitor with Sγ in Cys298 and taking into account the Oγ in residue Ser298 appearing in the activated form. In 
order to best mimic the physiological situation, we therefore suggest using irradiated protein in high-throughput 
drug discovery and drug development studies, including in vitro testing, to complement studies in site-directed 
mutants and to increase the rate of success of ARIs in subsequent clinical trials. The crystal structure of the irra-
diated hAR presented in this study (PDB: 6F8O), which includes the double modification C298S and C298A 
with respect to the native form, can also be employed as a target for an effective rational in silico drug discovery. 
The structure would allow taking into account and modeling the interactions between a lead molecule and the 
distinct active-site pocket of active hAR, especially near the residue 298. Furthermore, since the mechanisms that 
involve reactive species are common in oxidative stress and/or irradiation conditions, the controlled method of 
Figure 6. Indication that electrons are the main agent for the activation of hAR and proposed mechanism.  
(a) hAR activity in the presence of 10 mM uridine (red circles) and in the presence of 10 mM uridine plus 
40 mM sodium nitrate (gray circles) as a function of irradiation dose. (b) Number of non-thiolated cysteines per 
protein molecule as a function of dose, as measured by the Ellman’s assay. Accessible cysteines (in the absence 
of urea) are shown in gray, and buried cysteines (revealed in the presence of 8 M urea) are shown in yellow. 
(c) Scheme of the proposed mechanism for the C298S and C298A conversion induced by X-ray irradiation or 
oxidative stress. Carbon atoms are colored in cyan, carbon radicals in purple, oxygen atoms in red, and sulfur 
atoms in yellow. Hydrogen atoms are not shown for clarity.
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irradiation with X-rays presented in this work could become an instrumental approach to study other proteins 
that are also exposed to oxidative stress environments, like those related to cancer, Parkinson, Alzheimer or 
inflammatory diseases.
Methods
Protein purification and crystallization. The hAR cDNA obtained from Alexandra Cousido-Siah and 
Alberto Podjarny (IGBMC-CNRS-Univ. Strasbourg) was cloned into the pET-15b expression vector. The expres-
sion of the His6-tagged protein in Escherichia coli strain BL21 (DE3) pLysS was induced at 20 °C by 1 mM IPTG at 
OD600 0.8–1 and cells were incubated for 16 h in a 2 L culture. Then cells were disrupted by sonication and cen-
trifuged at 4 °C in 20 mM Tris-HCl pH 8.0, 250 mM NaCl, 5 mM imidazole buffer. The pellet was discarded and 
the supernatant was loaded in a nickel ion affinity chromatography column. The hAR was eluted in an imidazole 
gradient (5–250 mM). Then, thrombin cleavage of the His-tag was carried out overnight at 277 K. The buffer of 
the cleaved protein was changed to 50 mM ammonium citrate pH 5.0. The hAR crystals were grown by the hang-
ing drop vapor diffusion method. Ten μL of protein at 30 mg/mL with a NADPH:protein ratio of 2:1 was mixed 
with 10 μL of 50 mM ammonium citrate pH 5.0, 10% (w/v) polyethylene glycol (PEG) 6000 and 1 mM DTT. The 
solution was equilibrated at 4 °C for a week against a 500 μL reservoir, consisting of 20% PEG 6000 and 120 mM 
ammonium citrate, pH 5.0. After drop equilibration, nucleation was induced by seeding at room temperature. 
Crystals grew until its maximum size (around 0.8 mm long) in three days and finally they were transferred into 
a cryoprotecting solution consisting of 85 mM ammonium citrate pH 5.0 and 40% PEG 6000 prior to be loop-
mounted and stored in liquid nitrogen.
Protein irradiation in solution for the enzymatic assays. For a given sample, 3 μL at 2.3 mg/mL in 
20 mM Tris-HCl, 250 mM NaCl pH 8.0 were introduced inside a polyimide cylindrical capillary of 1 mm internal 
diameter and 0.025 mm wall thickness. The ends were sealed with vacuum grease to prevent liquid evapora-
tion. The capillary was placed in a magnetic base compatible with the BL13-XALOC goniometer (Supp. Fig. 5). 
Homogeneous irradiation was ensured by scanning the whole sample volume at uniform speed using a top-hat 
rectangular-shape X-ray beam of 200 × 180 μm2 (Supp. Fig. 5). The photon flux at sample was measured prior to 
each experiment by a calibrated Si PIN diode. The photon energy was set to 12.661 keV (0.979 Å).
Enzymatic assays. The hAR activity was determined with a Varian Cary 400 (UV/VIS) spectrophotom-
eter at 25 °C by monitoring at 340 nm the decrease of NADPH in 0.6 mL of 0.1 M sodium phosphate buffer pH 
7.4, containing 2 μL of irradiated or native enzyme, 0.2 mM NADPH and 10 µM–30 mM d,l-glyceraldehyde. For 
inhibition assays, activity was measured under the same conditions, in the presence of 6 mM d,l-glyceraldehyde. 
Concentrated stocks of inhibitors were prepared in DMSO and diluted in the reaction mixture to reach a final 
compound concentration close to the IC50 value in a final DMSO concentration of 1% (v/v). Control activity was 
performed in the presence of 1% (v/v) DMSO. All the experiments were performed at least in triplicate, using for 
each activity an independently irradiated protein sample.
From the slope of the absorbance vs time graph, the variation of absorbance per second was obtained, which 
was then converted to specific activity using NADPH molar extinction coefficient (ε = 6,220 M−1 cm−1), enzyme 
concentration and sample volume applied and protein molecular weight (35.9 kDa). Specific activities obtained 
for native protein at substrate concentrations ranging from 10 μM to 30 mM were fitted to the substrate inhibition 
equation:
=
∗
+ ∗ +( )
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In the case of 1kGy irradiated protein, as no significant substrate inhibition was observed in the tested concen-
trations, data was fitted to the Michaelis-Menten equation:
=
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MX data collection. Diffraction data collections at 100 K were performed in the BL13-XALOC beamline at 
the ALBA synchrotron using a Pilatus 6 M photon-counting detector (DECTRIS, Baden, Switzerland). The beam 
was set at 13.750 keV photon energy (λ = 0.9017 Å) and the sample-detector distance was adjusted to collect the 
datasets at a resolution of 0.90 Å. The attenuated photon flux during data collections was 1.2 × 1011 photons/s as 
measured using a calibrated Si PIN diode at the sample position. The beam profile had a top-hat circular shape 
and was defocused to 190 µm in diameter as measured by a Ce:YAG fluorescent screen at the sample position 
(Supp. Fig. 6). Twenty complete data sets (D1-D20) of 800 images each were collected with an angle increment 
of 0.25 deg and 0.1 s exposure time per image. The crystals were irradiated between datasets using a beam with a 
photon flux of 6.3 × 1011 photons/s to speed-up radiation damage effects. The total oscillation angle was identical 
for all burns and data collections.
MX data processing and structure refinement. All twenty datasets collected in the MX experiments 
were indexed and integrated using XDS54 in P21 space and cell parameters similar to those previously reported. 
The datasets were scaled and the structure factors generated using AIMLESS55 and TRUNCATE56, respectively. 
The resolution cutoff for each dataset was chosen so that Rmerge was around 30% in the last resolution shell. 
Following this criterion, the I/σI in the last resolution shell ranged between 3.6 and 4.7 for all the datasets (Supp. 
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Table 1). The initial phases to solve the structure of the D1 dataset were calculated from PDB entry 2J8T57 after 
removal of water molecules and alternative conformations with Phaser-MR58. To reduce the model bias, all the 
atom coordinates from the initial model were randomly shifted by 0.15 Å using PDBSET and the Cys298-Sγ and 
Cys298-Cβ atoms were removed. The initial phases for D2-D20 structures were extracted in the course of a refine-
ment process based on the previously solved structure after the removal of water molecules with a B-factor > 35 
Å2. All the structure refinements were carried out using SHELXL59. The examination of the density maps and the 
manual rebuilding of the model were done using Coot60. The refined parameters included atomic coordinates, 
atomic displacement parameters (ADP), and atomic occupancy. The bond length standard uncertainties were 
computed by inversion of the full normal matrix with SHELXL. No riding hydrogen atoms were included in 
the model. The difference Fourier maps were built using reflections between 50 Å and 1.2 Å resolution and were 
Wilson scaled together via SCALEIT61. The difference Fourier maps (Fobs,n − Fobs,1, αcalc,1) were calculated between 
each dataset n and the initial dataset using the phases of the fresh, not previously irradiated dataset, αcalc,1. The 
complete data collection and refinement statistics are listed in Supp. Tables 1 and 2 respectively. The crystal struc-
tures were deposited at the Protein Data Bank with PDB IDs 6F7R, 6F81, 6F82, 6F84 and 6F8O for datasets D1, 
D5, D10, D15 and D20, respectively.
MX structure alignment. The alignment between the crystallographic structures were carried out by 
LSQKAB using the method described by Kabsch62 between residues Ser2 and Phe311. The root mean square 
deviation (RMSD) of the C298 residue and that of the whole structure excluding the disordered terminal residues 
(Ser2 to Phe311) were calculated for the Cα, main chain, side chain and all atoms (Supp. Table 3).
SAXS data collection. SAXS data from B21 Beamline (Diamond Light Source, Didcot, United Kingdom) 
was obtained using a Pilatus 2 M photon-counting detector (DECTRIS, Baden, Switzerland) and a camera length 
of 4.014 m. The beam at the sample position was 4 mm (horizontal) × 0.96 mm (vertical) and had an incident flux 
of 8.5 × 1010 photons/s at 12.4 keV (λ = 0.999 Å). The hAR samples were measured in 100 mM sodium phosphate 
buffer, pH 7.4, at a concentration of 2.7 mg/ml. For the samples containing uridine, a 10x stock solution of the 
additive was prepared in the same buffer and ten-fold diluted to a final concentration of 10 mM prior to the 
measurements. All samples were analyzed in a cylindrical quartz capillary of 1.6 mm internal diameter with a wall 
thickness of 0.1 mm, held at 283 K under vacuum. Multiple frames of 10 s exposure time were recorded. The data 
were collected by using the BioSAXS sample changer robot63. The experiments were performed in static mode 
and without beam attenuation to speed-up radiation damage on the sample. The SAXS experiments with samples 
containing uridine were performed under the same conditions.
SAXS data analysis. Radius of gyration (Rg) was determined with the Guinier approximation64 by using 
the PRIMUS software65 included in the ATSAS package66. Radiation damage was monitored by the normalized 
radius of gyration calculation, Rg/Rg0, where Rg is the radius of gyration at a given dose and Rg0 is that obtained in 
the first data frame. An increase of more than 10% in the normalized radius of gyration is considered indicative 
of significant global structural radiation damage.
Dose calculations. The dose absorbed by the samples in the enzymatic and SAXS experiments was calcu-
lated by using the Lambert’s Law:
=
< > < >
D
F Trans E t Abs
m
in container sample,1
where Fin is the incoming photon flux, E is the photon energy, t is the accumulated exposure time, m is the mass 
of the irradiated sample, <Trans>container,1 is the average transmission coefficient for one side of the container and 
<Abs>sample is the average absorption coefficient for the irradiated sample.
For these experiments <Trans>container,1 was calculated following:
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where µ is the attenuation coefficient of the container at the used photon energy, ρ is the density of the container, 
Rext is the external radius and d is the beam path length through the container. <Trans>container,1 was calculated 
to be 0.992 for the polyimide container (µ = 1.494 cm2/g and ρ = 1.425 g/cm3) and 0.690 for the quartz container 
(µ = 9.804 cm2/g and ρ = 2.648 g/cm3) (Supp. Fig. 7).
In the case of enzymatic experiments, <Abs>sample was calculated from:
∫< > = − < > −Abs Trans R
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F
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R
out
in,1
2
in
in
where Fout is the output photon flux, <Trans>container,1 is taken from the polyimide container and Rin is the internal 
radius of the container. Fin and Fout(x) were measured experimentally by scanning the capillary the x direction 
with a calibrated Si PIN diode (Supp. Fig. 8). For enzymatic experiments <Abs>sample was calculated to be 0.256.
Since the protein concentration for the SAXS experiments was very low (~75 µM), the protein solution was 
approximated to be only water (µ = 2.673 cm2/g and ρ = 1 g/cm3). With this assumption, <Abs>sample can be cal-
culated through:
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where D is the beam path length through the sample. For SAXS experiments <Abs>sample was calculated to be 
0.282. All the attenuation lengths µ and density ρ values were extracted from the XCOM Photon Cross Sections 
Database (https://physics.nist.gov/cgi-bin/Xcom/xcom2). The average dose in the exposed region (AD-ER) for 
the MX experiments was calculated with RADDOSE-3D67.
Inhibitor compounds. Zenarestat (3-(4-bromo-2-fluorobenzoyl)-7-chloro-3,4-dihydro-2,4-dioxo-
1(2H)-quinazolineacetic acid) was generously provided by A. Podjarny. JF0048 (2-(3-(4-chloro-3-nitrob
enzyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetic acid) was a gift from A.R. de Lera (Univ. Vigo), and was 
synthesized as described previously31. Tolrestat was a kind gift of Prof. T.G. Flynn (Queen’s University, Kingston, 
Canada). Epalrestat was purchased from Sigma-Aldrich (reference SML0527).
Liquid chromatography– tandem mass spectrometry (LC-MS/MS). Proteins were manually 
digested with trypsin (Sequencing grade modified, Promega). Briefly, proteins were reduced by treatment with a 
solution of 20 mM DTT in 50 mM NH4HCO3 for 30 min at 56 °C, and then alkylated by treatment with a 50 mM 
solution of iodine acetamide for 30 min at room temperature. Proteins were digested overnight, at 37 °C with 
100 ng of trypsin. Tryptic peptides were cleaned up with C18 homemade stage tips. Eluted peptides were dried 
in a vacuum centrifuge. The dried-down peptide mixtures were re-suspended in 1% formic acid and analyzed 
in a nanoAcquity liquid chromatographer (Waters) coupled to a LTQ-Orbitrap Velos (Thermo Scientific) mass 
spectrometer. Peptides were trapped on a Symmetry C18TM trap column (5 μm particle size, 180 μm × 20 mm; 
Waters), and were separated using a C18 reverse phase capillary column (ACQUITY UPLC M-Class Peptide 
BEH column; 130 Å, 1.7 μm, 75 μm × 250 μm, Waters). The gradient used for the elution of the peptides was 1 to 
40% in 30 min, followed by a gradient from 40 to 60% in 5 min (A: 0.1% formic acid; B: 100% acetonitrile, 0.1% 
formic acid), with a 250 nL/min flow rate. Eluted peptides were subjected to electrospray ionization in an emitter 
needle (PicoTipTM, New Objective) with an applied voltage of 2000 V. For each irradiated, peptide masses (m/z 
300–1700) were analyzed in data dependent mode where a full Scan MS was acquired in the Orbitrap instrument 
with a resolution of 60,000 FWHM at m/z 400. Up to the 15 most abundant peptides (having a minimum inten-
sity of 500 counts) were selected from each MS scan and then fragmented in the linear ion trap using CID (38% 
normalized collision energy) with helium as the collision gas. The scan time settings were: Full MS: 250 ms (1 
microscan) and MSn: 120 ms. The scan time settings were 250 ms (2 microscan) for full MS, and 300 ms for MSn. 
The raw data files were collected and generated using Thermo Xcalibur (v.2.2). All the steps in the LC-MS/MS 
measurements were performed at the Plataforma de Proteòmica of the Parc Científic de Barcelona.
Analysis of non-thiolated cysteines. The reduction state of cysteines was assayed following the Pierce 
procedure for quantifying sulfhydryl groups based on molar absorptivity. Briefly, the reduced cysteines are 
detected by their reaction with 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB)68, which gives a product with a max-
imum absorbance at 412 nm. The reaction buffer used in the analysis of exposed cysteines consisted of 0.1 M 
sodium phosphate, 1 mM EDTA, pH 8.0. The reaction buffer used in the analysis of total cysteines added 8 M 
urea. The DTNB solution was prepared by mixing 4 mg of the reagent with 1 mL of reaction buffer (with or 
without urea). Two μL of the irradiated or native protein were mixed with 2.5 μL of reagent preparation and 
7.5 μL of reaction buffer, giving a final reaction volume of 10 μL. The reaction was left at room temperature until 
the measure was stable (from 15 min to 5 h). Experiments were carried out in triplicate for each dose and for the 
buffer with or without urea, and used native protein as a control for each dose measure. Absorbance at 412 nm 
was monitored with a Nanodrop 2000 (Thermo Scientific).
The number of reduced cysteines per protein molecule was calculated for each dose and the buffer with or 
without urea using the Lambert’s law corrected to take into account the protein concentration:
ε
=
∗ ∗
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/
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where ε is the extinction coefficient of DTNB and l is the path length, which was 0.1 cm in our setup. The values 
of the molar extinction coefficients were assumed to be ε = 14,150 and ε = 14,290 M−1·cm−1 for the native and the 
denaturing conditions, respectively.
Data Availability
The data generated by the enzymatic assays, the liquid chromatography-tandem mass spectrometry measure-
ments and the crystallography and small angle scattering experiments, including the raw images which support 
the findings of this study, are available from the Zenodo repository with the identifier https://doi.org/10.5281/ze-
nodo.1265630. The hAR structures obtained using datasets D1 (non-irradiated), D5, D15 and D20 (maximum ir-
radiation) are uploaded on the PDB database (www.rcsb.org) with ID 6F7R, 6F81, 6F82, 6F84, 6F8O, respectively.
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